Zinc in PDB 4fg3: Crystal Structure Analysis of the Human Insulin

The structure of Crystal Structure Analysis of the Human Insulin, PDB code: 4fg3 was solved by L.M.T.R.Lima, M.P.Favero-Retto, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	40.78 / 2.00
Space group	H 3
Cell size a, b, c (Å), α, β, γ (°)	81.559, 81.559, 33.538, 90.00, 90.00, 120.00
R / Rfree (%)	19.6 / 25.2

The structure of Crystal Structure Analysis of the Human Insulin also contains other interesting chemical elements:

Chlorine

(Cl)

2 atoms

The binding sites of Zinc atom in the Crystal Structure Analysis of the Human Insulin (pdb code 4fg3). This binding sites where shown within 5.0 Angstroms radius around Zinc atom.
In total 2 binding sites of Zinc where determined in the Crystal Structure Analysis of the Human Insulin, PDB code: 4fg3:
Jump to Zinc binding site number: 1; 2;

Zinc binding site 1 out of 2 in the Crystal Structure Analysis of the Human Insulin


Mono view


Stereo pair view

A full contact list of Zinc with other atoms in the Zn binding site number 1 of Crystal Structure Analysis of the Human Insulin within 5.0Å range: probe atom residue distance (Å) B Occ B:Zn101 b:24.1 occ:0.33 NE2 B:HIS10 2.1 14.6 1.0 CE1 B:HIS10 3.0 11.1 1.0 CD2 B:HIS10 3.2 17.9 1.0 CL B:CL102 3.3 39.3 0.3 O B:HOH212 4.0 37.5 1.0 ND1 B:HIS10 4.1 18.3 1.0 CG B:HIS10 4.3 20.0 1.0

Zinc binding site 2 out of 2 in the Crystal Structure Analysis of the Human Insulin


Mono view


Stereo pair view

A full contact list of Zinc with other atoms in the Zn binding site number 2 of Crystal Structure Analysis of the Human Insulin within 5.0Å range: probe atom residue distance (Å) B Occ D:Zn101 b:21.3 occ:0.33 NE2 D:HIS10 2.0 16.8 1.0 CL D:CL102 2.6 39.7 0.3 CE1 D:HIS10 3.0 17.6 1.0 CD2 D:HIS10 3.1 17.2 1.0 O D:HOH211 3.6 32.6 1.0 ND1 D:HIS10 4.1 18.4 1.0 CG D:HIS10 4.2 18.6 1.0

M.P.Favero-Retto, L.C.Palmieri, T.A.Souza, F.C.Almeida, L.M.Lima. Structural Meta-Analysis of Regular Human Insulin in Pharmaceutical Formulations. Eur J Pharm Biopharm V. 85 1112 2013.
ISSN: ISSN 0939-6411
PubMed: 23692694
DOI: 10.1016/J.EJPB.2013.05.005